Merck (MRK) Says FDA Accepted sBLA for its KEYTRUDA as Adjuvant Therapy in Advanced Melanoma
Tweet Send to a Friend
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
